Sam Chi serves as Vice President, Commercial and Portfolio Planning at Evommune. He is a seasoned commercial leader with over 20 years track record of success in various biopharma commercial roles spanning a wide range of therapeutic areas (immunology, hematology, metabolic, respiratory, dermatology, cardiology and oncology). Sam leverages his entrepreneurial DNA and passion for driving better therapeutic options for patients to successfully commercialized several breakthrough drugs, such as infliximab and belimumab, that continue to help many patients today.
Most recently, Sam served as the Head of Commercial at a stealth biopharmaceutical startup. Before that, he was the VP of Global Commercial Strategy and Program Team Leader for Oxbryta at Global Blood Therapeutics until its acquisition by Pfizer, Inc, where he led global commercialization strategy and lifecycle planning for Oxbryta, disease area strategy for two clinical stage assets, and provided strategic direction for two pre-clinical programs as well as business development efforts. He also formerly held sales and marketing roles with increasing responsibilities at Roche/Genentech, Dermira (acquired by Eli Lilly & Co), Human Genome Sciences (acquired by GSK) and Johnson & Johnson/Janssen.
Sam earned an MBA from Duke University, an MS in Physical Therapy from Columbia University, and a BA in Biology from Boston University.